Newsletter | January 7, 2026

01.07.26 -- Is 2026 The Year We End The 'Culture Wars' Between Sponsors And CDMOs?

SPONSOR

INDUSTRY INSIGHTS

Getting To The Heart Of CDMO Tech Transfer Excellence

Discover five key factors that drive a seamless and efficient technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success.

Accelerated API Manufacturing: Combining All Process Development Stages

During early-stage development, utilize the key considerations outlined in this paper to avoid common pitfalls and expedite the transition from molecule to market.

Reshaping Drug Development With 3D Screen Printing

Steven Facer and Laxxon Medical COO Klaus Kühne describe the capabilities of 3D screen printing for pharmaceutical production. Explore prototyping, IP protection, release profile possibilities, and more.

FEATURED EDITORIAL

Is 2026 The Year We End The 'Culture Wars' Between Sponsors And CDMOs?

No two cultures meld perfectly, but between any sponsor and CDMO lies a certain culture of manufacturing outsourcing that both sides should recognize. If 2025 was the year CDMOs focused on their customer service, let 2026 be the year sponsors do the same on your side. Biotechs and pharma alike should ask: “Does our culture enhance –  or inhibit – the outsourcing experience?”

Avoiding And Mitigating Delays In Outsourced Projects

This segment of the Outsourced Pharma Live event, “Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right,” examines the most common causes of timeline delays in outsourced small molecule development and offers practical strategies like contractual detail, contingencies, on-site presence, schedule buffers, and understanding CDMO internal turnaround times.

INDUSTRY INSIGHTS CONTINUED

From IND To NDA: The Role Of The Kilo Lab In A Seamless Scaleup

To derisk your manufacturing, work with an outsourcing partner that prioritizes the kilo lab as a space to develop a proven, robust, and reliable workflow from clinical to commercial scale.

Solving The Inhalation Puzzle: A CDMO's Guide To Dry Powder Development

Gain guidance on the choice of formulation, excipients, and the micronization technologies offered by CDMOs, and learn about current encapsulation technologies for inhaled products.

Time-To-Manufacture Reduced By 30% Through Rapid Transfer Strategy

Critical formulation deficiencies were solved through batch manufacturing and process adjustments. This enabled a 30% reduction in time-to-manufacture and prevented delays to the start date.

Driving Seamless Tech Transfer Of Multiple Projects Within A Short Timeline

Uncover how we were able to provide seamless technology transfers and uninterrupted production to deliver critical therapies efficiently and reliably to patients.

ICP-MS And ICP-OES: Tools For Elemental Impurity Analysis

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.

SOLUTIONS

Package Testing Services

Ensure your products and materials maintain integrity through distribution with robust package validation testing. Explore comprehensive capabilities including simulation and aging tests.

Improve The Bioavailability Of Poorly Soluble Drugs

KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies — in a fraction of the time of other amorphous solid dispersion technologies.

Sachet Packaging Solutions

See versatile, high-quality sachets for manufacturers and consumers with an ideal fill weight of 2 grams and above that is suitable for food or liquid formulas.

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: